Company
Voyageur Pharmaceuticals Ltd
CVE:VM
To become a vertically integrated global leader in medical imaging contrast media by developing cost-effective and best in class products. We are experts in mineral mining and processing. Our ownership of natural barium and iodine resources within North America enables us to implement a strategy aimed at building a stable supply chain for imaging products critical for patient diagnosis. We have assembled a team of contrast media experts and world leading radiologists to drive our decision making for this important patient-led initiative, the starting point being several Health Canada licenses already approved for barium contrast media. Voyageur is now working with the FDA to register our products in the US market, whilst creating a drug dossier for the European and International markets. Our long term vision is to serve both the barium and iodine contrast media markets, from a fully integrated supply chain: “From The Earth To The Bottle”.
56 stories · page 3 of 3
Voyageur Pharmaceuticals aims to be the first vertically-integrated North American supplier of medical imaging contrast agents
The Canadian company plans to ensure North America has a reliable supply chain of high-quality, green pharmaceuticals
Voyageur Pharmaceuticals accelerates revenue generation timeline for Frances Creek barium sulphate project
The plant, which will be located in Alberta, Canada, is designed to process approximately 5,000 tonnes per year of Frances Creek US Pharmacopeia (USP) grade barium sulfate (barite) concentrate
Voyageur Pharmaceuticals signs MOU to develop fullerene contrast agents for medical imaging applications and carbon capture technology
“Voyageur has been on a multi-year quest to find a high quality, dependable supply of fullerenes for its radiology contrast media drug pipeline,” said Brent Willis, the company's CEO.